These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 34795215)

  • 1. Genetic fusions favor tumorigenesis through degron loss in oncogenes.
    Liu J; Tokheim C; Lee JD; Gan W; North BJ; Liu XS; Pandolfi PP; Wei W
    Nat Commun; 2021 Nov; 12(1):6704. PubMed ID: 34795215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PPP1R1B-STARD3 chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of PI3K/AKT signaling.
    Yun SM; Yoon K; Lee S; Kim E; Kong SH; Choe J; Kang JM; Han TS; Kim P; Choi Y; Jho S; Yoo H; Bhak J; Yang HK; Kim SJ
    Oncogene; 2014 Nov; 33(46):5341-7. PubMed ID: 24276243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
    Gao Q; Liang WW; Foltz SM; Mutharasu G; Jayasinghe RG; Cao S; Liao WW; Reynolds SM; Wyczalkowski MA; Yao L; Yu L; Sun SQ; ; ; Chen K; Lazar AJ; Fields RC; Wendl MC; Van Tine BA; Vij R; Chen F; Nykter M; Shmulevich I; Ding L
    Cell Rep; 2018 Apr; 23(1):227-238.e3. PubMed ID: 29617662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic interaction between Tmprss2-ERG gene fusion and Nkx3.1-loss does not enhance prostate tumorigenesis in mouse models.
    Linn DE; Bronson RT; Li Z
    PLoS One; 2015; 10(3):e0120628. PubMed ID: 25780911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCDC6, a gene product in fusion with different protoncogenes, as a potential chemotherapeutic target.
    Laxmi A; Gupta P; Gupta J
    Cancer Biomark; 2019; 24(4):383-393. PubMed ID: 30909182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
    Parker BC; Annala MJ; Cogdell DE; Granberg KJ; Sun Y; Ji P; Li X; Gumin J; Zheng H; Hu L; Yli-Harja O; Haapasalo H; Visakorpi T; Liu X; Liu CG; Sawaya R; Fuller GN; Chen K; Lang FF; Nykter M; Zhang W
    J Clin Invest; 2013 Feb; 123(2):855-65. PubMed ID: 23298836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting interactome network perturbations in human cancer: application to gene fusions in acute lymphoblastic leukemia.
    Hajingabo LJ; Daakour S; Martin M; Grausenburger R; Panzer-Grümayer R; Dequiedt F; Simonis N; Twizere JC
    Mol Biol Cell; 2014 Dec; 25(24):3973-85. PubMed ID: 25273558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Three Novel Fusion Oncogenes, SQSTM1/NTRK3, AFAP1L2/RET, and PPFIBP2/RET, in Thyroid Cancers of Young Patients in Fukushima.
    Iyama K; Matsuse M; Mitsutake N; Rogounovitch T; Saenko V; Suzuki K; Ashizawa M; Ookouchi C; Suzuki S; Mizunuma H; Fukushima T; Suzuki S; Yamashita S
    Thyroid; 2017 Jun; 27(6):811-818. PubMed ID: 28351223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rare but Recurrent ROS1 Fusions Resulting From Chromosome 6q22 Microdeletions are Targetable Oncogenes in Glioma.
    Davare MA; Henderson JJ; Agarwal A; Wagner JP; Iyer SR; Shah N; Woltjer R; Somwar R; Gilheeney SW; DeCarvalo A; Mikkelson T; Van Meir EG; Ladanyi M; Druker BJ
    Clin Cancer Res; 2018 Dec; 24(24):6471-6482. PubMed ID: 30171048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models.
    Okamoto K; Kodama K; Takase K; Sugi NH; Yamamoto Y; Iwata M; Tsuruoka A
    Cancer Lett; 2013 Oct; 340(1):97-103. PubMed ID: 23856031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene fusions in tumourigenesis with particular reference to ovarian cancer.
    Zhou Y; El-Bahrawy M
    J Med Genet; 2021 Dec; 58(12):789-795. PubMed ID: 34462289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer.
    Tomlins SA; Laxman B; Dhanasekaran SM; Helgeson BE; Cao X; Morris DS; Menon A; Jing X; Cao Q; Han B; Yu J; Wang L; Montie JE; Rubin MA; Pienta KJ; Roulston D; Shah RB; Varambally S; Mehra R; Chinnaiyan AM
    Nature; 2007 Aug; 448(7153):595-9. PubMed ID: 17671502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering and Functional Characterization of Fusion Genes Identifies Novel Oncogenic Drivers of Cancer.
    Lu H; Villafane N; Dogruluk T; Grzeskowiak CL; Kong K; Tsang YH; Zagorodna O; Pantazi A; Yang L; Neill NJ; Kim YW; Creighton CJ; Verhaak RG; Mills GB; Park PJ; Kucherlapati R; Scott KL
    Cancer Res; 2017 Jul; 77(13):3502-3512. PubMed ID: 28512244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung.
    Shin DH; Lee D; Hong DW; Hong SH; Hwang JA; Lee BI; You HJ; Lee GK; Kim IH; Lee YS; Han JY
    Oncotarget; 2016 Oct; 7(43):69450-69465. PubMed ID: 27626312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tumor-associated YAP1 fusions identifies a recurrent set of functions critical for oncogenesis.
    Szulzewsky F; Arora S; Hoellerbauer P; King C; Nathan E; Chan M; Cimino PJ; Ozawa T; Kawauchi D; Pajtler KW; Gilbertson RJ; Paddison PJ; Vasioukhin V; Gujral TS; Holland EC
    Genes Dev; 2020 Aug; 34(15-16):1051-1064. PubMed ID: 32675324
    [TBL] [Abstract][Full Text] [Related]  

  • 16. annoFuse: an R Package to annotate, prioritize, and interactively explore putative oncogenic RNA fusions.
    Gaonkar KS; Marini F; Rathi KS; Jain P; Zhu Y; Chimicles NA; Brown MA; Naqvi AS; Zhang B; Storm PB; Maris JM; Raman P; Resnick AC; Strauch K; Taroni JN; Rokita JL
    BMC Bioinformatics; 2020 Dec; 21(1):577. PubMed ID: 33317447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovering and understanding oncogenic gene fusions through data intensive computational approaches.
    Latysheva NS; Babu MM
    Nucleic Acids Res; 2016 Jun; 44(10):4487-503. PubMed ID: 27105842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis.
    Pajtler KW; Wei Y; Okonechnikov K; Silva PBG; Vouri M; Zhang L; Brabetz S; Sieber L; Gulley M; Mauermann M; Wedig T; Mack N; Imamura Kawasawa Y; Sharma T; Zuckermann M; Andreiuolo F; Holland E; Maass K; Körkel-Qu H; Liu HK; Sahm F; Capper D; Bunt J; Richards LJ; Jones DTW; Korshunov A; Chavez L; Lichter P; Hoshino M; Pfister SM; Kool M; Li W; Kawauchi D
    Nat Commun; 2019 Sep; 10(1):3914. PubMed ID: 31477715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET rearrangements are actionable alterations in breast cancer.
    Paratala BS; Chung JH; Williams CB; Yilmazel B; Petrosky W; Williams K; Schrock AB; Gay LM; Lee E; Dolfi SC; Pham K; Lin S; Yao M; Kulkarni A; DiClemente F; Liu C; Rodriguez-Rodriguez L; Ganesan S; Ross JS; Ali SM; Leyland-Jones B; Hirshfield KM
    Nat Commun; 2018 Nov; 9(1):4821. PubMed ID: 30446652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
    Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
    Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.